Company registration number 00560985 (England and Wales)
PEACOCKS (SURGICAL AND MEDICAL EQUIPMENT) LIMITED
FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 30 NOVEMBER 2024
PAGES FOR FILING WITH REGISTRAR
PEACOCKS (SURGICAL AND MEDICAL EQUIPMENT) LIMITED
COMPANY INFORMATION
Directors
C D Peacock
G E Cooper
J C Peacock
D W Stevens
Company number
00560985
Registered office
Unit C1
Benfield Business Park
Benfield Road
Newcastle upon Tyne
NE6 4NQ
Auditor
Azets Audit Services
Bulman House
Regent Centre
Gosforth
Newcastle upon Tyne
NE3 3LS
PEACOCKS (SURGICAL AND MEDICAL EQUIPMENT) LIMITED
CONTENTS
Page
Statement of financial position
1
Statement of changes in equity
2
Notes to the financial statements
3 - 9
PEACOCKS (SURGICAL AND MEDICAL EQUIPMENT) LIMITED
STATEMENT OF FINANCIAL POSITION
AS AT
30 NOVEMBER 2024
30 November 2024
- 1 -
30 November 2024
31 May 2023
Notes
£
£
£
£
Fixed assets
Intangible assets
3
4,225
16,697
Tangible assets
4
34,553
40,733
38,778
57,430
Current assets
Stocks
660,508
475,989
Debtors
5
1,367,186
1,786,279
Cash at bank and in hand
229,687
2,406,802
2,257,381
4,669,070
Creditors: amounts falling due within one year
6
(917,258)
(1,261,124)
Net current assets
1,340,123
3,407,946
Total assets less current liabilities
1,378,901
3,465,376
Provisions for liabilities
-
0
(9,354)
Net assets
1,378,901
3,456,022
Capital and reserves
Called up share capital
8,518
8,518
Other reserves
33,419
33,419
Profit and loss reserves
1,336,964
3,414,085
Total equity
1,378,901
3,456,022

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the income statement within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 18 November 2025 and are signed on its behalf by:
C D Peacock
Director
Company registration number 00560985 (England and Wales)
PEACOCKS (SURGICAL AND MEDICAL EQUIPMENT) LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE PERIOD ENDED 30 NOVEMBER 2024
- 2 -
Share capital
Capital contribution reserve
Profit and loss reserves
Total
Notes
£
£
£
£
Balance at 1 June 2022
8,518
-
3,506,527
3,515,045
Year ended 31 May 2023:
Loss and total comprehensive income
-
-
(62,373)
(62,373)
Dividends
-
-
(30,069)
(30,069)
Other movements
-
33,419
-
33,419
Balance at 31 May 2023
8,518
33,419
3,414,085
3,456,022
Period ended 30 November 2024:
Loss and total comprehensive income
-
-
(1,438,101)
(1,438,101)
Dividends
-
-
(639,020)
(639,020)
Balance at 30 November 2024
8,518
33,419
1,336,964
1,378,901
PEACOCKS (SURGICAL AND MEDICAL EQUIPMENT) LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 30 NOVEMBER 2024
- 3 -
1
Accounting policies
Company information

Peacocks (Surgical and Medical Equipment) Limited is a private company limited by shares incorporated in England and Wales. The registered office is Unit C1, Benfield Business Park, Benfield Road, Newcastle upon Tyne, NE6 4NQ.

1.1
Reporting period

The financial statements have been prepared for the period 1 June 2023 to 30 November 2024. As such, the comparative information may not be comparable.

1.2
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.3
Going concern

Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

The company meets its day to day working capital requirements through cash generated from operations along with the use of an invoice discounting facility.

 

The company’s forecasts and projections for the next twelve months show that the company should be able to continue in operational existence for that period, taking into account reasonable possible changes in trading performance.

1.4
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Other income

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

 

Government grants relating to turnover are recognised as income over the periods when the related costs are incurred. Grants relating to an asset are recognised in income systematically over the asset's expected useful life. If part of such a grant is deferred it is recognised as deferred income rather than being deducted from the asset's carrying amount.

1.5
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

PEACOCKS (SURGICAL AND MEDICAL EQUIPMENT) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 30 NOVEMBER 2024
1
Accounting policies
(Continued)
- 4 -

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Software development
33% Straight line
1.6
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold improvements
25% Straight line
Plant and machinery
33% Straight line
Tooling and equipment
33% Straight line
Motor vehicles
33% Straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.7
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.8
Financial instruments
Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.9
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

PEACOCKS (SURGICAL AND MEDICAL EQUIPMENT) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 30 NOVEMBER 2024
1
Accounting policies
(Continued)
- 5 -
Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the income statement, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.10
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.11
Share-based payments

Equity-settled share-based payments are measured at fair value at the date of grant by reference to the fair value of the equity instruments granted using the Black Scholes model. The fair value determined at the grant date is expensed on a straight-line basis over the vesting period, based on the estimate of shares that will eventually vest. A corresponding adjustment is made to equity.

When the terms and conditions of equity-settled share-based payments at the time they were granted are subsequently modified, the fair value of the share-based payment under the original terms and conditions and under the modified terms and conditions are both determined at the date of the modification. Any excess of the modified fair value over the original fair value is recognised over the remaining vesting period in addition to the grant date fair value of the original share-based payment. The share-based payment expense is not adjusted if the modified fair value is less than the original fair value.

 

Cancellations or settlements (including those resulting from employee redundancies) are treated as an acceleration of vesting and the amount that would have been recognised over the remaining vesting period is recognised immediately.

1.12
Leases
As lessee

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

PEACOCKS (SURGICAL AND MEDICAL EQUIPMENT) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 30 NOVEMBER 2024
- 6 -
2
Employees

The average monthly number of persons (including directors) employed by the company during the period was:

2024
2023
Number
Number
Total
15
16

The number of directors who exercised share options during the period was 0 (2023 - 1).

3
Intangible fixed assets
Software development
£
Cost
At 1 June 2023 and 30 November 2024
24,945
Amortisation and impairment
At 1 June 2023
8,248
Amortisation charged for the period
12,472
At 30 November 2024
20,720
Carrying amount
At 30 November 2024
4,225
At 31 May 2023
16,697
4
Tangible fixed assets
Leasehold improvements
Plant and machinery
Tooling and equipment
Motor vehicles
Total
£
£
£
£
£
Cost
At 1 June 2023
2,568
110,073
47,326
29,047
189,014
Additions
-
0
25,122
-
0
-
0
25,122
At 30 November 2024
2,568
135,195
47,326
29,047
214,136
Depreciation and impairment
At 1 June 2023
2,568
107,159
30,477
8,077
148,281
Depreciation charged in the period
-
0
14,720
2,059
14,523
31,302
At 30 November 2024
2,568
121,879
32,536
22,600
179,583
PEACOCKS (SURGICAL AND MEDICAL EQUIPMENT) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 30 NOVEMBER 2024
4
Tangible fixed assets
Leasehold improvements
Plant and machinery
Tooling and equipment
Motor vehicles
Total
£
£
£
£
£
(Continued)
- 7 -
Carrying amount
At 30 November 2024
-
0
13,316
14,790
6,447
34,553
At 31 May 2023
-
0
2,914
16,849
20,970
40,733
5
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
238,127
403,953
Corporation tax recoverable
-
0
132,006
Amounts owed by group undertakings
368,464
363,836
Other debtors
733,167
732,109
Prepayments and accrued income
27,428
154,375
1,367,186
1,786,279
6
Creditors: amounts falling due within one year
2024
2023
£
£
Trade creditors
464,986
715,752
Taxation and social security
85,670
235,794
Deferred income
270,016
261,366
Accruals and deferred income
96,586
48,212
917,258
1,261,124
7
Audit report information

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006.

The auditor's report is unqualified and includes the following:

Opinion

In our opinion the financial statements:

PEACOCKS (SURGICAL AND MEDICAL EQUIPMENT) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 30 NOVEMBER 2024
7
Audit report information
(Continued)
- 8 -
Senior Statutory Auditor:
Claire Hinshaw ACCA
Statutory Auditor:
Azets Audit Services
Date of audit report:
19 November 2025
8
Financial commitments, guarantees and contingent liabilities

Included in the statement of financial position are unpaid pension contributions of £8,272 (2023 - £17,885).

9
Operating lease commitments
As lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2024
2023
£
£
Total commitments
128,555
32,385
10
Related party transactions
Transactions with related parties

The company has taken advantage of the exemption available under paragraph 33.1A of FRS 102 and does not disclose related party transactions with members of the same group that are wholly owned.

11
Directors' transactions

During the period the directors were provided with a loan facility. The loans were interest free and repayable on demand.

Dividends totalling £0 (2023: £0) were paid in the period in respect of shares held by the company's directors.

Description
% Rate
Opening balance
Amounts advanced
Amounts repaid
Closing balance
£
£
£
£
C D Peacock  - Loan Account
-
594,931
300,000
(595,226)
299,705
G E Cooper - Loan Account
-
105,000
-
(10,985)
94,015
D W Stevens  - Loan Account
-
10,000
311,626
(32,957)
288,669
709,931
611,626
(639,168)
682,389
12
Parent company

The most senior parent entity producing publicly available financial statements is The Peacock Group Limited, incorporated in England and Wales. These financial statements are available upon request from Unit C1, Benfield Business Park, Benfield Road, Newcastle upon Tyne, Tyne and Wear, NE6 4NQ.

PEACOCKS (SURGICAL AND MEDICAL EQUIPMENT) LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 30 NOVEMBER 2024
12
Parent company
(Continued)
- 9 -

The ultimate controlling party is J C Peacock.

2024-11-302023-06-01falsefalsefalse19 November 2025CCH SoftwareCCH Accounts Production 2025.300No description of principal activityC D PeacockG E CooperJ C PeacockD W Stevens005609852023-06-012024-11-3000560985bus:Director12023-06-012024-11-3000560985bus:Director22023-06-012024-11-3000560985bus:Director32023-06-012024-11-3000560985bus:Director42023-06-012024-11-3000560985bus:RegisteredOffice2023-06-012024-11-30005609852024-11-30005609852023-05-3100560985core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-11-3000560985core:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-05-3100560985core:LandBuildings2024-11-3000560985core:PlantMachinery2024-11-3000560985core:FurnitureFittings2024-11-3000560985core:MotorVehicles2024-11-3000560985core:LandBuildings2023-05-3100560985core:PlantMachinery2023-05-3100560985core:FurnitureFittings2023-05-3100560985core:MotorVehicles2023-05-3100560985core:WithinOneYear2024-11-3000560985core:WithinOneYear2023-05-3100560985core:CurrentFinancialInstruments2024-11-3000560985core:CurrentFinancialInstruments2023-05-3100560985core:ShareCapital2024-11-3000560985core:ShareCapital2023-05-3100560985core:OtherMiscellaneousReserve2024-11-3000560985core:OtherMiscellaneousReserve2023-05-3100560985core:RetainedEarningsAccumulatedLosses2024-11-3000560985core:RetainedEarningsAccumulatedLosses2023-05-3100560985core:ShareCapital2022-05-3100560985core:RetainedEarningsAccumulatedLosses2022-05-3100560985core:RetainedEarningsAccumulatedLosses2022-06-012023-05-31005609852022-06-012023-05-3100560985core:RetainedEarningsAccumulatedLosses2023-06-012024-11-3000560985core:IntangibleAssetsOtherThanGoodwill2023-06-012024-11-3000560985core:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-06-012024-11-3000560985core:LandBuildingscore:LongLeaseholdAssets2023-06-012024-11-3000560985core:PlantMachinery2023-06-012024-11-3000560985core:FurnitureFittings2023-06-012024-11-3000560985core:MotorVehicles2023-06-012024-11-3000560985core:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-05-3100560985core:LandBuildingscore:LeasedAssetsHeldAsLessee2023-05-3100560985core:PlantMachinery2023-05-3100560985core:FurnitureFittings2023-05-3100560985core:MotorVehicles2023-05-31005609852023-05-3100560985core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-11-3000560985core:LandBuildingscore:LeasedAssetsHeldAsLessee2023-06-012024-11-3000560985bus:PrivateLimitedCompanyLtd2023-06-012024-11-3000560985bus:SmallCompaniesRegimeForAccounts2023-06-012024-11-3000560985bus:FRS1022023-06-012024-11-3000560985bus:Audited2023-06-012024-11-3000560985bus:FullAccounts2023-06-012024-11-30xbrli:purexbrli:sharesiso4217:GBP